Background: Metabolic syndrome (MetS) is also known as syndrome X, insulin resistance syndrome is dened as a group of disease developed due to accumulation of multiple risk factors that includes resistance to insulin, dyslipidemia, abdominal obesity and hypertension. Metabolic syndrome, is associated not only with type 2 diabetes mellitus and cardiovascular disease, but also with many other systemic disorders such as cerebrovascular accident, chronic lung disease and fatty liver disease. Hyperuricemia (above 7.0 mg/dL in men and 6.0 mg/dL in women) has been reported to be closely related to diabetes, hypertension, obesity, renal function decline, and cardiovascular disease, most of which are principal contributors in the development and progression of MetS. The study aimed to assess the associations of serum uric acid with the components of MetS. Methods: This cross-sectional study was conducted in the hospitals attached to Bangalore medical college and research Institute. 110 patients with metabolic syndrome who satised the inclusion criteria were included. Data was collected in the form of history, clinical examination, and relevant investigations. Statistical analysis was performed using SPSS software, p value of <0.5 being signicant Results: The mean age of the study participants was found to be 51.55+7.760 years of age. 62.7% of the study participants were males The mean serum uric acid level of the study participants was found to be 6.325+2.7910. 41.82% of the study participants who had metabolic syndrome had hyperuricemia. The association was found to be statistically signicant between hyperuricemia and hypertension, central obesity, low HDL, high FBS among the study participants. Conclusions: Serum uric acid is closely associated with metabolic syndrome and its components. Serum uric acid can also be considered as a mandatory investigation in patients who has any of the ve components of metabolic syndrome
Background: Hepatitis associated aplastic anemia (HAA); is a form of acquired aplastic anemia in which bone marrow failure develops after an acute attack of hepatitis. Aplastic anemia can also be seen after liver transplantation due to acute fulminant hepatitis. Aims: In this study, we aimed to define clinical and labarotory characteristics, possible causes, treatment strategies and and clinical outcome in patients with HAA.
There is no prior study analyzing the prognosis for hepatocellular carcinoma (HCC) by adding the tumor factor (i.e., tumor burden score) to the Controlling Nutritional Status (CONUT) score. This study aimed to investigate the effect of the CONUT plus tumor burden (CONUT-TB) score as a prognostic factor in patients with HCC after liver resection. Method: Data were reviewed from 96 consecutive patients treated by curative liver resection for HCC between January 2015 and December 2018. Repeated liver resection (n=14) and combined resection of the metastatic lesion (n=1) were excluded. Patients were divided into two groups according to the CONUT-TB score calculated by receiver operating characteristics (ROC) curves. Result: The optimal cutoff value of the CONUT-TB score was 8. Among the 81 patients included in the analytic cohort, 61 patients had low (<8) and 20 patients had high (>8) CONUT-TB score. The overall survival rate at 3 years following liver resection for HCC in the high CONUT-TB group was 71.8% compared to 91.3% in the low CONUT-TB group (p=0.007). Multivariate analysis indicated that high CONUT-TB score (hazard ratio: 6.19, 95% CI: 1.48 to 25.92, p=0.013) was independently associated with overall survival after liver resection.
Conclusion:The CONUT-TB score is valuable predictor of survival in patients with HCC after liver resection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.